Clinical Research Directory
Browse clinical research sites, groups, and studies.
Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival
Sponsor: London School of Economics and Political Science
Summary
This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the survival benefits of new cancer drugs
Official title: Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival: a Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3000
Start Date
2026-08-01
Completion Date
2026-10-01
Last Updated
2026-07-28
Healthy Volunteers
No
Conditions
Interventions
FDA explanation for progression-free survival (control)
Progression-free survival
FDA explanation for progression-free survival with overall survival data
The description, 'progression-free survival', along with data on overall survival.
NCI explanation for progression-free survival
The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse'.
NCI explanation for progression-free survival with overall survival data
The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse', along with data on overall survival.
Plain-language explanation of progression-free survival
The description, 'the length of time until a test showed the cancer grew, spread, or worsened'.
Plain-language explanation of progression-free survival with overall survival data
The description, 'the length of time until a test showed the cancer grew, spread, or worsened', along with data on overall survival.
Locations (1)
Harvard Medical School and Harvard Pilgrim Health Care Institute
Boston, Massachusetts, United States